Will I Need Eye Injections for Diabetic Macular Edema Forever?
Diabetic Macular Edema Injections at a Glance
Call your eye doctor the same day if any of these start in the days after an injection. Go to an emergency room if you cannot reach the office.
- Severe eye pain, or pain that keeps getting worse
- A red and painful eye, or new light sensitivity
- Decreased vision, or a shower of new floaters
The drug label for one of these medicines tells patients to report eye pain, redness of the eye, light sensitivity, or blurring of vision without delay, because these can be the first signs of an infection inside the eye1. That infection is rare. In one study of 652,421 injections, it showed up about once in every 2,857 shots2. Most injection days end with nothing worse than a scratchy, pink eye for a day. Knowing the signs and calling the same day is what keeps a rare problem from becoming a lasting one.
For most people, the answer is no, though nobody can promise a schedule in advance. In a five-year randomized trial of ranibizumab injections for diabetic macular edema, participants received a median of 13 to 17 injections in total, and during year five, 62 of every 100 people in one group and 52 of every 100 in the other received no injections at all3. The first year is the busy one. After that, most schedules thin out. Some people do keep going for years, and that is not a failure. It means the medicine is still doing a job your eye needs done.
Diabetes damages the tiny blood vessels in the retina, the light-sensing layer at the back of your eye. When those leaky vessels flood the macula, the small central patch of retina you use for reading and faces, the tissue swells, and vision turns blurry, wavy, or washed out in color4. The medical name for it is macular edema (clinical: fluid buildup in the macula). The injections aim squarely at drying that fluid out.
Treatment is not one fixed course with an end date. It responds to what your macula does month by month. A common pattern is roughly 6 to 8 injections in the first year, 2 to 3 in the second, 1 to 2 in the third, and 0 to 1 in the fourth and fifth years, with monitoring visits continuing after injections become rare5. Your own count may sit above or below that. Your retina doctor adjusts as the scans change.
What Diabetic Macular Edema Is and Who Gets It
High blood sugar over years weakens the walls of the smallest retinal vessels. They begin to leak fluid and fats. Starved tissue also releases a signal protein called VEGF, which makes vessels leakier still. That is the loop the injections interrupt. Anti-VEGF medicines block that signal and can slow or undo the swelling4. Your diabetes drives the loop, which is why eye treatment and diabetes care are one project, not two.
Risk is not evenly spread. Anyone with type 1, type 2, or gestational diabetes can develop diabetic retinopathy, and risk climbs the longer you have had diabetes and when blood pressure or cholesterol also runs high6. Higher hemoglobin A1c and longer diabetes duration were both linked to macular edema in a large US sample7. None of this is a verdict, and several of these are things you and your medical team can move.
You are far from alone in this waiting room. In a national US survey, about 4 of every 100 adults aged 40 and older with diabetes had this swelling, or roughly 746,000 people7. Most retina practices run injection clinics several days a week.
Swelling can be well underway before anything feels wrong. The early stages of diabetic retinopathy usually cause no symptoms at all6. When symptoms do arrive, they are usually blurry central vision, straight lines that look bent, and dull colors4. One eye can be worse than the other, and you may not notice until you cover one. That early silence is why the yearly dilated exam matters more than how your vision feels today.
How Your Eye Doctor Confirms and Tracks the Swelling
Two things happen at almost every visit. Your doctor checks for macular edema during a dilated eye exam, which is simple and painless. A scanner called optical coherence tomography, or OCT, then takes cross-section pictures of the retina4. The scan gives a thickness number for the center of your macula. Tracked visit to visit, that number is the main dial your doctor watches.
Sometimes the scan alone does not explain what is happening. A test called fluorescein angiography uses an injected dye to photograph the blood vessels in your retina and can show where fluid is leaking from4. It helps when your doctor is weighing laser for a specific leaking spot, or checking blood flow.
A drier macula usually buys you a longer gap. Your doctor compares today's thickness with your own recent history, not a universal target, and pairs it with your reading vision. If both hold steady, the interval lengthens; if fluid returns, it shortens again. That back-and-forth is normal, and one thicker scan rarely changes the long-run plan.
What the Injections Are and What a Visit Is Like
The medicine goes into the vitreous, the clear gel filling the eye, so it acts where the leaking is. Anti-VEGF medicines injected into the eye are effective for treating diabetic macular edema that involves the center of the macula and has cost you vision8. It does not repair damaged vessels. It quiets the leak signal for weeks, letting the macula dry and vision recover. When the drug wears off, the signal can return. That is why repeat doses exist.
Most people find it far less dramatic than they feared. Your eye is numbed with drops or gel, then cleaned with an antiseptic. A small lid holder keeps you from blinking, and the injection itself takes a second or two. Afterward you may notice a gritty feeling, a red spot on the eye, and a few floaters for a day.
Early treatment is front-loaded, often monthly at first, because a swollen macula needs several doses in a row before it dries and stays dry. That is what the year-one average of roughly 6 to 8 injections reflects, and it drops off in later years5. The stretch that feels endless in month three is usually the part you will not repeat.
Most retina clinics now use a treat-and-extend approach. You are treated at each visit, and if the macula stays dry, the next appointment is pushed out. If fluid comes back, the interval is pulled in. With one newer medicine, faricimab, given this way, more than 60 of every 100 participants were on every-16-week dosing by week 96 of two phase 3 trials9. Fewer visits, same goal.
How Many Injections People Actually Need, Year by Year
This is the closest thing to a real answer available. In DRCR Protocol I, five-year totals came to a median of 13 injections in one arm and 17 in the other. By year four, 54 of every 100 and 45 of every 100 participants got no injections at all that year3. Vision held onto most of its early gain. So the honest framing is not 'forever.' It is 'a lot at first, much less later, with check-ups continuing.'
| Year of treatment | Typical injections that year |
|---|---|
| Year 1 | About 6 to 8 |
| Year 2 | About 2 to 3 |
| Year 3 | About 1 to 2 |
| Years 4 and 5 | About 0 to 1 |
Two eyes with the same diagnosis can need very different schedules. In the Protocol T extension study, 68 of every 100 eyes had at least one more injection between years two and five, a median of 4 across that whole stretch10. Longer-standing diabetes, higher A1c, and stubborn swelling tend to mean more doses, while a macula that dries fast and stays dry means fewer. Your doctor cannot know which you are until treatment is underway.
Stopping is a decision to make with your retina doctor, not on your own after a good visit. In one look-back study, stopping these injections without the swelling returning was uncommon, and a longer dry stretch went with a better chance of stopping11. Fluid that comes back quietly can take vision with it. So the practical move is not to quit, but to keep the monitoring visits even when injections pause.
Sometimes the right number of injections right now is zero. One trial looked at eyes with center swelling and good vision of 20/25 or better. Watching closely, or using laser, and injecting only if vision dropped gave no clear difference in vision loss at two years12. Guidelines agree that treatment may reasonably wait until vision is affected8. This works only if you come to the follow-up visits.
Other Treatments That Can Lower Your Injection Burden
Steroids attack the swelling through inflammation rather than VEGF. A dexamethasone implant is biodegradable and releases medicine into the vitreous over a period of months13, while a fluocinolone acetonide implant carrying 0.19 mg of drug is built as a 36-month sustained-release system14. Both are labeled for diabetic macular edema in the United States. The trade-off is the usual steroid warnings. The dexamethasone label states that use of corticosteroids may produce clouding at the back of the lens (clinical: posterior subcapsular cataract), increased eye pressure, and glaucoma13. The fluocinolone label states that corticosteroid use may result in that same kind of cataract, and that prolonged use may lead to glaucoma with damage to the optic nerve14. Your doctor checks your eye pressure at follow-up visits, and a cataract that starts blurring your vision can be removed with surgery, so these are things that get watched for rather than sprung on you.
Laser had the field before injections arrived and still has a role. Certain laser treatments can be used for macular edema4. Focal laser targets specific leaking spots rather than the whole macula. It is most useful when the swelling sits away from the center of your vision. Some doctors add it alongside injections to slow how often fluid comes back.
Three anti-VEGF medicines are used most. One of them, bevacizumab (Avastin), carries a label for cancer given into a vein, with no eye indication listed, so its use for macular swelling is off-label15. It costs a fraction as much, so many insurers ask for it first. In one trial, starting with bevacizumab and switching to aflibercept when needed gave two-year vision of 14.0 letters gained versus 15.0 letters for aflibercept alone, and 70 of every 100 bevacizumab-first eyes were switched16.
Surgery is a later option, not a starting point. In a vitrectomy the surgeon makes small openings in the eye wall and removes most of the vitreous gel. It may be recommended when other treatments have not worked4. Doctors most often consider it when scar tissue on the retina is tugging the macula, because no injection can undo that pulling. Recovery is longer, and vision gains are less predictable.
What You Can Do Between Visits
This is the part of the plan you hold. In one landmark trial in people with type 1 diabetes, tight blood sugar control lowered the risk of developing retinopathy by about three quarters, and slowed worsening by about half in those who already had eye damage17. Managing your diabetes helps prevent or delay vision loss. High blood pressure and cholesterol raise the risk further6. Better numbers will not empty your calendar, but they change the odds you are playing.
A one-minute home check catches changes between visits. Cover one eye and look at a doorframe or an Amsler grid. Note whether straight lines look bent or a patch is missing, then repeat with the other eye. Do it about the same time each week, watching for change from your own baseline. If something shifts, call the office rather than waiting for your next visit.
Practical logistics make the schedule easier to sustain. Vision is often blurry for a few hours after dilation, so arrange a ride for the first few visits until you know how you react. Many people book early appointments and return to work afterward, and ask their employer for a recurring half-day rather than explaining each absence.
Risks, Costs, and a Realistic Outlook
Most side effects are mild and short. A red patch on the white of the eye comes from a tiny broken vessel. It looks alarming but usually clears on its own over one to two weeks. Grittiness, watering, and a few new floaters are common for a day. What is not expected is pain that worsens, vision that drops, or light that becomes hard to tolerate.
Serious problems are uncommon but real, which is why the same-day rule exists. One large series recorded 231 infections across 652,421 injections, about once in every 2,8572. A US claims analysis found a higher rate, 498 infections across 818,558 injections, about once in every 1,63918. Retinal detachment and a pressure rise are also possible. Caught early, these are treatable. That is the whole reason to report symptoms the same day.
Population averages are not a personal forecast, and your own path may differ. In the Protocol T extension, average vision at five years was still about 7 letters better than at the start, though it had slipped about 5 letters from the two-year mark10. Protocol I held mean gains of about 7 to 10 letters at five years3. Sticking with follow-up keeps a slow drift from becoming a sharp drop.
Cost is a legitimate part of this conversation, not a side issue. Medicare and most commercial plans cover these injections, though copays and step-therapy rules vary a lot, and many plans ask for the lower-cost off-label medicine first. Ask the practice for a benefits check and about manufacturer assistance programs. Doses missed over cost are a treatment problem, so raise it early instead of skipping visits.
When to Call Your Eye Doctor and Who Should Lead Your Care
Beyond the post-injection signs above, call the same day for a sudden drop in vision, a dark curtain across your field, or a burst of floaters with flashes. Bleeding inside the eye can cause dark floating spots or cobweb-like streaks, and it is important to get treatment right away; advanced diabetic retinopathy can also pull the retina away from the back of the eye6. You will not be wasting anyone's time. Eye clinics expect these calls.
Some changes are less urgent but should not wait for your next slot. Call within a week for reading vision that has slipped, straight lines that look newly bent, a new dull patch in the center, or a persistent ache. Also call if you will miss an appointment, because rescheduling protects your interval plan far better than quietly dropping off the calendar.
These injections are given by a retina specialist, an eye surgeon with extra training in the back of the eye. Your optometrist or general eye doctor often makes the referral and keeps up your routine care. Everyone with diabetes should have a dilated eye exam at least once a year, and more often once retinopathy is found6. Guidelines set the first exam within five years of a type 1 diagnosis, then at least yearly19.
Questions People Ask About Long-Term Eye Injections
Possibly, but only with close monitoring rather than by dropping out. In eyes with center swelling and vision of 20/25 or better, watching closely and injecting only if vision fell matched immediate injections at two years12. That result depends on returning for scans so treatment can start the moment things shift. Skipping the visits, not the injections, is what turns this option into a risk.
Most people describe pressure rather than sharp pain, because the surface is numbed first. The needle is fine and the injection takes a couple of seconds. A gritty feeling for several hours afterward is typical, and artificial tears help. Many patients say the third and fourth visits feel far easier, mainly because the unknown is gone. Tell your doctor if pain is more than mild.
Do not assume the damage is done, and do not let embarrassment keep you away. Fluid often returns when treatment lapses, and vision can slip with it. In many eyes, restarting brings the swelling back down, though some vision lost over a long gap may not fully return. Call and get back on the schedule, and say what got in the way, since cost and transport are common and fixable.
It genuinely helps the underlying disease, but treat it as a partner to the injections, not a replacement. Tight blood sugar control lowered the risk of retinopathy developing and slowed its progression in a landmark type 1 diabetes trial17. No one can tell you it will shorten your own injection course. Lowering A1c very fast can briefly worsen retinopathy, so make big changes with your diabetes team and eye doctor both informed.
They are worth raising, especially if the visit burden is wearing you down. In two phase 3 trials of faricimab on a treat-and-extend schedule, about 80 of every 100 participants were on every-12-week or longer dosing by week 969. Longer gaps are not automatic, and insurance may require other medicines first. Ask what interval your doctor thinks your eye could tolerate.
Often yes, and many practices do it to halve the number of trips. When both eyes are injected in one visit, practices use separate sterile instruments and separate drug lots for each eye, which is done to keep a problem in one eye from reaching the other. Some doctors stagger the first few sessions to see how you respond.
More Questions About Living With Injection Treatment
No. They control the leaking that swells your macula, but they do not repair the damaged vessels underneath. That is why fluid can come back when the drug wears off. Anti-VEGF medicines can slow or undo the swelling4, and that often means real vision gains. Think of it as ongoing disease control, like blood pressure medication, not a one-time repair.
Not precisely at the start, and be wary of anyone offering a fixed number. Your doctor gets a much better sense after three to six months, once they see how fast your macula dries and how long it stays dry. A longer unbroken dry period went with a better chance of eventually stopping11. Your early response is one of the more useful signals available.
Yes, and this is the most commonly missed part of the plan. Monitoring visits continue even when injections become rare5. Swelling can return without you noticing at first, and catching it on a scan beats catching it when reading gets hard. Expect your intervals to lengthen over time rather than your appointments to end.
Tell your doctor plainly that you want to review the plan. Options after a poor response include switching to a different anti-VEGF medicine, adding focal laser, or moving to a steroid implant. Steroid implants are generally held for eyes where anti-VEGF dries the macula poorly or wears off too fast5. Stubborn swelling is a signal to change strategy, not a signal that nothing more can be done.
- Is my swelling in the center of the macula, and what is my current OCT thickness?
- What interval are we aiming for, and what would make you extend or shorten it?
- Which medicine am I getting, and does my insurance require a different one first?
- If my macula stays dry, at what point would we try pausing injections?
- How often will I still need scans if injections stop?
- Who do I call after hours if I get pain or vision loss following an injection?
- US Food and Drug Administration label via DailyMed (2025). EYLEA (aflibercept) injection, for intravitreal use: US prescribing information.
- Ophthalmology (2024). Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections.
- Elman MJ, et al. Ophthalmology (2015). Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment: 5-Year Randomized Trial Results (DRCR Protocol I).
- National Eye Institute (NIH) (2025). Macular Edema.
- EyeNet Magazine, American Academy of Ophthalmology (2023). Diabetic Macular Edema: Personalizing Treatment.
- National Eye Institute (NIH) (2025). Diabetic Retinopathy.
- Varma R, et al. JAMA Ophthalmology (2014). Prevalence of and Risk Factors for Diabetic Macular Edema in the United States.
- American Academy of Ophthalmology (2025). Diabetic Retinopathy Preferred Practice Pattern (2025).
- Ophthalmology (2024). Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results From the Randomized Phase 3 YOSEMITE and RHINE Trials.
- Glassman AR, et al. Ophthalmology (2020). Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
- Scientific Reports (2025). Predictive Value of Uninterrupted Dry Macula Duration for Discontinuation of Anti-VEGF Therapy in Diabetic Macular Edema.
- Baker CW, et al. JAMA (2019). Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity (DRCR Protocol V).
- US Food and Drug Administration label via DailyMed (2024). OZURDEX (dexamethasone intravitreal implant) 0.7 mg: US prescribing information.
- US Food and Drug Administration label via DailyMed (2025). ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg: US prescribing information.
- US Food and Drug Administration label via DailyMed (2025). AVASTIN (bevacizumab) injection, for intravenous use: US prescribing information.
- Jhaveri CD, et al. New England Journal of Medicine (2022). Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema (DRCR Protocol AC).
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH) (2024). Blood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC.
- British Journal of Ophthalmology (2018). Endophthalmitis Rates Among Patients Receiving Intravitreal Anti-VEGF Injections: A USA Claims Analysis.
- American Diabetes Association, Diabetes Care (2026). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes 2026.